Latest Rigel Pharmaceuticals (RIGL) Headlines R
Post# of 101
Posted On: 03/13/2014 1:55:41 AM
Latest Rigel Pharmaceuticals (RIGL) Headlines
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Rigel (RIGL) Worth Watching: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:46AM CST
Rigel was a big mover last session, as the company saw its shares rise over 10% on the day.
Why Rigel Pharmaceuticals, Inc. Shares Popped
Alex Planes, The Motley Fool - Motley Fool - Thu Mar 06, 12:50PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rigel Pharmaceuticals are trading about...
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Rigel Announces Publication of R118 AMPK Activator Research
PR Newswire - Thu Mar 06, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation...", provides strong preclinical evidence that R118 may be useful in treating peripheral artery disease (PAD), a chronic and progressive vascular disease effecting nearly 5% of the population over the age of 50, and related metabolic disorders. This publication extends work from a previous Rigel publication on the mechanism and impact of AMPK activation. The Company also announced that it has commenced Phase 1 clinical studies with R118 as a potential treatment for Intermittent Claudication (IC), a painful and debilitating outcome of PAD.
Stock to Watch: Rigel Pharmaceuticals Up 6.8% (RIGL)
Comtex SmarTrend(R) - Wed Mar 05, 11:40AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.8% to $3.95 on 2.5x average daily volume. Rigel Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 703,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's -0.2%) and outperformed the S&P 500 (6.8% to the S&P's -0.0%) during today's trading.
Rigel Pharmaceuticals posts lower net loss of USD89.0m in 2013
M2 - Wed Mar 05, 6:21AM CST
Drug company Rigel Pharmaceuticals (NasdaqGS:RIGL) on Tuesday reported a net loss of USD89.0m (USD1.02 per basic and diluted share) for the year ended 31 December 2013.
Rigel Announces Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Tue Mar 04, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Rigel Announces Participation at Two Investor Conferences
PR Newswire - Thu Feb 27, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows:
Rigel Pharmaceuticals Up 6.1%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Mon Feb 24, 10:12AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.1% to $3.66 on 1.8x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 1.1 million shares, vs. average volume of 615,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.9%) and outperformed the S&P 500 (6.1% to the S&P's 0.9%) during today's trading.
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
PR Newswire - Fri Jan 10, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below). Information will be included about two fostamatinib clinical programs commencing in the first half of the year, a Phase 3 clinical study in patients with immune thrombocytopenic purpura (ITP) and a Phase 2 clinical study aimed at treating IgA nephropathy. Additionally, Rigel announced that it has earned a milestone payment of $5.75 million from AstraZeneca for the continued development of R256 in asthma.
INEC to Conduct Elections in Borno, Others If Security Situation Improves
All Africa Global Media - Wed Dec 18, 4:41AM CST
The Independent National Electoral Commission (INEC) said on Tuesday that it would conduct elections in states under emergency rule, if the security situation in those states improved.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Rigel Narrows Loss, Shares Continue to Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 1:14PM CST
Rigel Pharma reported narrower than expected loss in the third quarter.
Muscle Atrophy - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ch6m2/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2013" report to their offering. 'Muscle Atrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Muscle Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Atrophy. Scope - A snapshot of the global therapeutic scenario for Muscle Atrophy. - A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Muscle Atrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Eli Lilly and Company Rigel Pharmaceuticals, Inc. Fate Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/5c...le_atrophy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rigel Pharmaceuticals Inc's net loss narrows to USD23.8m in Q3 2013
M2 - Wed Nov 06, 5:55AM CST
Rigel Pharmaceuticals Inc (NasdaqGS:RIGL) stated on Tuesday its net loss of USD23.8m (USD0.27 per share) for the third quarter ended 30 September 2013.
Rigel Announces Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 05, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2013.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Rigel (RIGL) Worth Watching: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:46AM CST
Rigel was a big mover last session, as the company saw its shares rise over 10% on the day.
Why Rigel Pharmaceuticals, Inc. Shares Popped
Alex Planes, The Motley Fool - Motley Fool - Thu Mar 06, 12:50PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rigel Pharmaceuticals are trading about...
Rigel Rises on Narrower Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:40AM CST
Rigel Pharma's 4Q13 loss of 19 cents per share was narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of 30 cents per share
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Rigel Announces Publication of R118 AMPK Activator Research
PR Newswire - Thu Mar 06, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation...", provides strong preclinical evidence that R118 may be useful in treating peripheral artery disease (PAD), a chronic and progressive vascular disease effecting nearly 5% of the population over the age of 50, and related metabolic disorders. This publication extends work from a previous Rigel publication on the mechanism and impact of AMPK activation. The Company also announced that it has commenced Phase 1 clinical studies with R118 as a potential treatment for Intermittent Claudication (IC), a painful and debilitating outcome of PAD.
Stock to Watch: Rigel Pharmaceuticals Up 6.8% (RIGL)
Comtex SmarTrend(R) - Wed Mar 05, 11:40AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.8% to $3.95 on 2.5x average daily volume. Rigel Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 703,000 shares per day. The stock has outperformed the Dow (6.8% to the Dow's -0.2%) and outperformed the S&P 500 (6.8% to the S&P's -0.0%) during today's trading.
Rigel Pharmaceuticals posts lower net loss of USD89.0m in 2013
M2 - Wed Mar 05, 6:21AM CST
Drug company Rigel Pharmaceuticals (NasdaqGS:RIGL) on Tuesday reported a net loss of USD89.0m (USD1.02 per basic and diluted share) for the year ended 31 December 2013.
Rigel Announces Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Tue Mar 04, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Rigel Announces Participation at Two Investor Conferences
PR Newswire - Thu Feb 27, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows:
Rigel Pharmaceuticals Up 6.1%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Mon Feb 24, 10:12AM CST
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 6.1% to $3.66 on 1.8x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 1.1 million shares, vs. average volume of 615,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.9%) and outperformed the S&P 500 (6.1% to the S&P's 0.9%) during today's trading.
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
PR Newswire - Fri Jan 10, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below). Information will be included about two fostamatinib clinical programs commencing in the first half of the year, a Phase 3 clinical study in patients with immune thrombocytopenic purpura (ITP) and a Phase 2 clinical study aimed at treating IgA nephropathy. Additionally, Rigel announced that it has earned a milestone payment of $5.75 million from AstraZeneca for the continued development of R256 in asthma.
INEC to Conduct Elections in Borno, Others If Security Situation Improves
All Africa Global Media - Wed Dec 18, 4:41AM CST
The Independent National Electoral Commission (INEC) said on Tuesday that it would conduct elections in states under emergency rule, if the security situation in those states improved.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Rigel Narrows Loss, Shares Continue to Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 1:14PM CST
Rigel Pharma reported narrower than expected loss in the third quarter.
Muscle Atrophy - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ch6m2/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2013" report to their offering. 'Muscle Atrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Muscle Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Atrophy. Scope - A snapshot of the global therapeutic scenario for Muscle Atrophy. - A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Muscle Atrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Eli Lilly and Company Rigel Pharmaceuticals, Inc. Fate Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/5c...le_atrophy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rigel Pharmaceuticals Inc's net loss narrows to USD23.8m in Q3 2013
M2 - Wed Nov 06, 5:55AM CST
Rigel Pharmaceuticals Inc (NasdaqGS:RIGL) stated on Tuesday its net loss of USD23.8m (USD0.27 per share) for the third quarter ended 30 September 2013.
Rigel Announces Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 05, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2013.
(0)
(0)Rigel Pharmaceuticals Inc. (RIGL) Stock Research Links
Scroll down for more posts ▼